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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.015Obese patients have worse outcomes during acute pancreatitis (AP). Previous animal models of AP have
found worse outcomes in obese rodents who may have a baseline proinﬂammatory state. Our aim was to
study the role of acute lipolytic generation of fatty acids on local severity and systemic complications of AP.
Human postpancreatitis necrotic collectionswere analyzed for unsaturated fatty acids (UFAs) and saturated
fatty acids. A model of biliary AP was designed to replicate the human variables by intraductal injection of
the triglyceride glyceryl trilinoleate alone or with the chemically distinct lipase inhibitors orlistat or ceti-
listat. Parameters of AP etiology and outcomes of local and systemic severity were measured. Patients with
postpancreatitis necrotic collections were obese, and 13 of 15 had biliary AP. Postpancreatitis necrotic
collections were enriched in UFAs. Intraductal glyceryl trilinoleate with or without the lipase inhibitors
resulted in oil red Oepositive areas, resembling intrapancreatic fat. Both lipase inhibitors reduced the
glyceryl trilinoleateeinduced increase in serum lipase, UFAs, pancreatic necrosis, serum inﬂammatory
markers, systemic injury, and mortality but not serum alanine aminotransferase, bilirubin, or amylase. We
conclude that UFAs are enriched in human necrotic collections and acute UFA generation via lipolysis
worsens pancreatic necrosis, systemic inﬂammation, and injury associated with severe AP. Inhibition of
lipolysis reduces UFA generation and improves these outcomes of AP without interfering with its induction.
(Am J Pathol 2014, 184: 1773e1784; http://dx.doi.org/10.1016/j.ajpath.2014.02.015)Supported by grant RO1DK092460 (V.P.S.), the Clinical Translational
Science Institute supported by the National Institutes of Health through
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package from the Department of Medicine, University of Pittsburgh
(V.P.S.). This project used the Luminex Core Laboratory, University of
Pittsburgh Cancer Institute Cancer Biomarkers Facility, which is supported
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Disclosures: None declared.The mystique of acute pancreatitis (AP) lies in its diverse
origins, unpredictable course, and outcomes, ranging from
resolution with minimal care to being a debilitating, pro-
tracted, and potentially lethal condition despite intensive
care and complex interventions to manage its complications.
The course AP takes seems unrelated to the origin in most
cases, with differences in the predominant origin of AP
reported in studies from different countries.1e5 However,
studies have repeatedly reported a higher body mass index
(BMI) or obesity to be associated with severe AP (SAP).1e8
SAP may result from severe pancreatic necrosis, in which
>30% of the pancreas is necrosed,9,10 or from persistent or
multisystem organ failure, such as respiratory and renal
failure. Obese patients have been reported to be more prone
to both these types of complications of AP.18
In contrast to the clinical scenario, conventional animal
models of AP differ in the initiating factor used, and thestigative Pathology.
.severity associated with these has been attributed to the
inciting stimulus11e13 or species in which the model has been
executed.12e15 For example, rat intraductal bile salteinduced
pancreatitis has been classiﬁed as severe in contrast to the
caerulein model, which is mild.12,13 Interestingly, caerulein-
induced AP is milder in rats than in mice, which have more
pancreatic necrosis, and thus mouse caerulein pancreatitis is
classiﬁed as severe.14,15 However, in both these cases, the
pancreas returns to normal a few days after cessation of the
Durgampudi et alinsult, with no residual necrotic areas or organ failure. On the
basis of such models, a potential target is regarded as thera-
peutically relevant if it plays a role in mechanistically
dissimilar models of AP. An example of this is phosphati-
dylinositol 3-kinases and associated trypsin genera-
tion,11,16,17 which we and others have previously found to be
relevant to AP of different causes.11,16,17
This discord (ie, the lack of association of outcomes to
cause as noted clinically) and how animal models are
interpreted have resulted in serious discrepancies between
what is predicted to be beneﬁcial in animal models of AP
and the success of such interventions in clinical trials. The
failure of serine protease and trypsin inhibition to improve
outcomes of AP in >70 clinical trials performed during the
last 5 decades is a classic example.18e27
Recently, the mechanistic proof of obesity being a mod-
iﬁer of AP outcomes has emerged, with the same model
being mild in lean mice and severe in obese mice, associated
with an exaggerated inﬂammatory response and mortality.28
Our recent studies have found that lipolysis of visceral fat in
obese mice may contribute to this severity.29 However,
obesity is also associated with a baseline proinﬂammatory
state,30e32 and because fatty acids (FAs) are proin-
ﬂammatory,29,33,34 it has yet to be decided whether short-
term generation of FAs by the lipolysis of visceral fat or
the preexistent inﬂammatory state associated with obesity
determines the severity of AP in these models.
We therefore analyzed human postpancreatitis necrotic
collections (PPNCs) for the nature of FAs in them. We also
noted the most common cause of AP in our patients.
Because biliary AP was the most common type of AP and
unsaturated FAs (UFAs) were abundant in PPNCs, we
studied whether their acute lipolytic generation in rats,
which are otherwise normal, results in the severe outcomes
noted in SAP and whether inhibition of such lipolysis, using
2 distinct lipase inhibitors separately, alters the initiation of
AP or the parameters of its severity. Interestingly, we realize
that the beneﬁcial effect of lipase inhibition, which de-
creases the generation of UFAs, is independent of the
initiation of biliary AP. These ﬁndings have relevance to
how we design and interpret animal models of AP in the
context of human disease.
Materials and Methods
Human Pancreatic Fluid Collections
Pancreatic necrosis ﬂuids and corresponding information on
age, sex, BMI, primary diagnosis, duration of disease at the
time of intervention, and ﬂuid source were collected as a part
of a pancreatic waste ﬂuid protocol between December 2010
and June 2012 at the University of Pittsburgh Medical Center,
Pittsburgh, Pennsylvania, and at the Washington University
Medical Center, St. Louis, Missouri. The diagnosis of
pancreatic necrosis was made based on clinical and imaging
criteria.35 After collection, all samples were transported1774immediately or shipped overnight on ice to the laboratory.
Freezing was avoided at this step to minimize repeated freeze
and thaw as would occur at the time of aliquoting and before
analysis. Moreover, because these collections had accumu-
lated at body temperature during at least 4 weeks, a single
freeze would unlikely improve preservation. The samples
were spun at 300 g for 5 minutes, and the supernatants were
sonicated, aliquoted, and frozen at 80C until they were
analyzed later after a single thaw. The Biospecimen Reporting
for Improved Study Quality criteria36 are fulﬁlled by these
details. Approval was obtained from the institutional review
boards at the University of Pittsburgh Medical Center and at
Washington UniversityMedical Center and the Committee for
Oversight of Research Involving the Dead at the University of
Pittsburgh Medical Center.
Animals and Animal Procedures
Male, 250- to 300-g Wistar rats (Charles River Laboratories,
Wilmington, MA) were used after a minimum of 2 days of
acclimatization. They were fed standard laboratory chow and
allowed to drink ad libitum until the night before the surgery
at which time they were fasted. Housing was at temperatures
ranging from 21C to 25C, with a 12-hour light-dark cycle.
Animals were anesthetized with ketamine-xylazine with
sterile precautions. Then 50 mL/100 g of body weight of
glyceryl trilinoleate (GTL) (Sigma, St. Louis, MO) alone or
with 50 mg/mL of orlistat dissolved in GTL (Cayman
Chemical, Ann Arbor, MI; GTLO group) or 25 mg/mL of
cetilistat dissolved in GTL (Jinan Wedo Industrial Co., Ltd.,
Jinan City, China; GTLC group) was injected into the
pancreatic duct of rats. This was followed by ligating the
biliopancreatic duct just proximal to its entry into the duo-
denum. The GTL dose (5% to 10% of pancreas volume,
based on the rat pancreas weighing approximately 0.5 to 1 g/
100 g of body weight37,38) was chosen to be in the range of
intrapancreatic fat (23.4%  4.3%) and percentage fat ne-
crosis (12.6%  3.4%) noted histologically in patients with
SAP.29 Fat necrosis contributes to most pancreatic paren-
chymal necrosis during SAP in humans.29,39 Preliminary
studies found that duct ligation alone without infusion
resulted in mild biliary AP at 1 day evidenced by a transient
increase in serum amylase and lipase (more than fourfold
above normal), serum alanine transaminase (ALT; > 300
U/L), bilirubin (>3 mg/dL), and pancreatic edema (79%
versus 73% in controls), all with a P < 0.01 versus controls
but with nomortality during 5 days. The intraductal route was
preferred over the intraparenchymal route to avoid hemor-
rhage. Postoperatively, the animals were administered
buprenorphine for pain control, cefazolin to prevent in-
fections, and 10 mL of saline subcutaneously daily. They
were followed up for 5 days (survival) or sacriﬁced at the
time near mortality (moribund). In separate studies, the
GTLO and GTLC groups were also electively sacriﬁced the
morning after duct ligation, by which time there was 100%
mortality in the GTL group. Serum and pancreas tissue wereajp.amjpathol.org - The American Journal of Pathology
Figure 1 Lipolysis of intrapancreatic unsaturated triglyceride contrib-
utes to parenchymal necrosis. Millimolar concentrations (A) and proportions
(as percentage total, B) of SFAs and UFAs in PPNCs from patients in whom
UFA in both amounts (PZ 0.033) and proportions (P < 0.001) are signif-
icantly higher than SFA amounts and proportions. Comparisons between the
groups are depicted with box plots showing mean (dashed line), median
(solid line), the 25th and 75th percentiles (upper and lower parts of the box
plot divided by the median line), the 10th and 90th percentile (whiskers),
and the outliers (dots). Serial sections of pancreatic tissue from a patient
with AP at the time of autopsy stained for H&E (C) and von Kossa (D). Note
the loss of cell outlines and morphologic detail in the parenchyma (signi-
fying parenchymal necrosis; dotted outline) surrounding the fat necrosis
(amorphous blue look of adipocytes on H&E and brown staining on von
Kossa) and the presence of lesser intense brown staining in the necrosed
parenchyma, suggestive of leakage of contents from the fat necrosis. Oil red
Oestained pancreatic cryosections from rats belonging to the control (E),
GTL (F), GTLO (G), and GTLC (H) groups. Note the accumulation of oil red
Oepositive staining is associated with loss of cellular detail with GTL but not
with GTLO or GTLC, supporting the dependence of this on lipolysis of the
triglyceride. Original magniﬁcation: 4 (C and D); 40 (EeH).
UFAs Worsen Acute Pancreatitisharvested to study levels of cytokines and lipotoxic mediators
and for morphologic analysis as described below. There were
8 to 10 animals in each group. All experiments were
approved by the Institutional Animal Care and Use Com-
mittee of the University of Pittsburgh.
Acinar Harvest and in Vitro Assays
Pancreatic acini were harvested40e42 and preincubated with
50 mmol/L orlistat29 or cetilistat, after which linoleic acid
(LA)29 or GTL was added, followed by incubation for 4
hours. At the end of which, cell death was measured by
lactate dehydrogenase (LDH) leakage29 or glycerol gener-
ation was measured29 to quantify GTL hydrolysis. The
methods are described in the articles referenced.
Cytokine Assays
As previously described,29 cytokine assays were performed on
serum samples using the ﬂuorescence-based capture sandwich
immunoassay (Luminex) on samples without severe hemoly-
sis. The MILLIPLEX MAP Rat Cytokine-Chemokine Mag-
netic beads panel fromMillipore (Billerica, MA) was used for
this. The samples were analyzed at the Luminex Core Facility
of the University of Pittsburgh Cancer Institute.
Evaluation of Pancreatic Necrosis and Special Stains
Whole pancreas H&E-stained sections were examined by a
trained pathologist (S.N.) blinded to the sample, as described
previously.29,40 Brieﬂy, all parenchymal areas were imaged
with a 4 objective and photographed. Necrotic area and
total parenchymal area were measured in pixels, and per-
centage of total area necrosed was calculated for each
pancreas. Oil red O staining was performed on pancreatic
cryosections as described previously.29 For pancreatic sec-
tions from autopsies, the slides of patients were procured and
stained with H&E or von Kossa as described previously.29,39
Terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) staining was performed on parafﬁn
sections of the lungs and kidneys as described previously.29
Nonesteriﬁed FA Analysis
As previously described, nonesteriﬁed FA analysis was
performed using gas chromatography29 on samples for
which an adequate volume (at least 25 mL) was available.
Total UFA amounts were calculated by adding individual
C16:1, C18:1, C18:2, and C20:4 FAs.
Serum Analyses
Serum ALT, total bilirubin (on nonhemolyzed samples to
avoid interference with the assay), serum amylase, lipase, and
blood urea nitrogen (BUN) were measured following
the manufacturer’s (Pointe Scientiﬁc Inc., Canton, MI)The American Journal of Pathology - ajp.amjpathol.orginstructions. Tests were performed on a ChemWell-T
chemistry analyzer (Awareness Technology, Palm City, FL).
Statistical Analysis
All values unless otherwise speciﬁed are reported as
means  SEM. All data were collected as continuous var-
iables. Pairs were compared using the U-test. P < 0.05 was1775
Durgampudi et alconsidered to indicate statistical signiﬁcance. This was
adjusted for multiple comparisons when comparing more
than two groups.Results
UFAs Are Higher in Human PPNCs
Patientswith PPNCswere obese (BMI, 36 1.8). In 13 of these
15 patients, the cause of PPNCs was biliary AP. Gas1776chromatographic analysis of the PPNC ﬂuids revealed that
UFAs were signiﬁcantly higher than saturated FAs (SFAs),
both in amount (2.7  1.0 mmol/L versus 1.0  0.3 mmol/L,
P Z 0.033) (Figure 1A) and as a percentage of total
(68.5% 3.0% versus 31.7% 2.9%, P< 0.001) (Figure 1B).
On the basis of i) a high level of UFAs in the PPNCs; ii)
histologic evidence that areas of fat necrosis (Fig 1, C and
D) have surrounding parenchymal necrosis (areas with loss
of cell outline surrounded by the dotted line), which has also
been reported previously29,39,43,44; iii) pancreatic lipases
leaking basolaterally into fat in human AP,45,46 allowing
hydrolysis of adipocyte triglyceride; iv) previous studies
reporting that UFAs but not SFAs saponify47; v) previous
evidence that UFAs cause acinar necrosis29,39; vi) the
ﬁnding that unhydrolyzed triglyceride within normal adi-
pocytes in the pancreas (Figure 1, C and D) is not sur-
rounded by acinar necrosis; and vii) the patients with
PPNCs being obese and having biliary pancreatitis, we
designed a model to replicate this pathophysiology.
This model involved intraductal injection of GTL to allow
for its lipolysis by lipases. GTLwas injected alone or with the
lipase inhibitors orlistat or cetilistat in separate animals to
study the effect of lipase inhibition on the course of AP. In-
jection of these lipids resulted in oil red Oepositive areas in
the pancreas (Figure 1, FeH) simulating the intrapancreatic
fat of obesity. In the absence of lipase inhibitors, the red areas
had loss of cellular detail suggestive of necrosis (Figure 1F).
Both orlistat (Figure 1G) and cetilistat (Figure 1H) caused the
accumulation of oil red Oepositive droplets; however,
cellular details were preserved.
Thus, this model could potentially allow for the mixing of
pancreatic lipases with triglyceride as would occur with
basolateral leakage of lipases during AP45,46,4851 with
consequent hydrolysis of adipocyte triglyceride, morpho-
logically seen as intrapancreatic fat necrosis in obese pa-
tients with SAP (Figure 1, C and D).29,39,44e46 This model
also involves pancreatic duct obstruction as a result of
ligating the biliopancreatic duct after GTL injection just
proximal to the duodenum. Preliminary studies have noted
that the sole act of such a duct ligation within 1 day resultsFigure 2 Inhibition of lipolysis does not affect parameters used to di-
agnose the onset of biliary AP. Serum amylase (A), bilirubin (B), and ALT (C)
as measured in controls (CON) and animals with an intraductal infusion of
GTL at the time when they were moribund (GTL) and those with an infusion of
GTLO and GTLC on day 1 and day 5. Comparisons between the groups are
depicted with box plots showingmean (dashed line), median (solid line), the
25th and 75th percentiles (upper and lower parts of the bars), the 10th and
90th percentile (whiskers), and the outliers (dots). Note that there is no
difference in serum amylase and bilirubin levels among the GTL, GTLO, and
GTLC groups at day 1 and that the ALT level, although lower in the GTLO group
compared with the GTL group, is still signiﬁcantly elevated compared with
controls. At day 5 the serum amylase level is signiﬁcantly lower in the GTLO
and GTLC groups (even lower than in controls) consistent with resolved AP,
whereas the bilirubin level remains elevated consistent with persistent
biliary obstruction. The ALT level was signiﬁcantly reduced in both groups, as
is typically noted in chronic biliary obstruction in humans. *P< 0.05 versus
control; yP < 0.05 versus the GTL group.
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Figure 3 Inhibition of lipolysis is associated with a reduction in serum
UFAs. Elevation of serum lipase (A) induced by GTL infusion is reduced in the
GTLO and GTLC groups on day 1 (when the moribund animals in the GTL group
were sacriﬁced), consistent with the role of orlistat and cetilistat as lipase
inhibitors. This ﬁnding was associated with the lipase inhibitors preventing
an increase in both the concentration (B) and proportion (C) of UFAs induced
by GTL. The lipase levels remained signiﬁcantly reduced at day 5 and similar
to amylase (Figure 2A) returned to near normal. Comparisons between the
groups are depicted with box plots showing mean (dashed line), median
(solid line), the 25th and 75th percentiles (upper and lower parts of the
bars), the 10th and 90th percentile (whiskers), and the outliers (dots).
*P < 0.05 versus control; yP < 0.05 versus the GTL group.
UFAs Worsen Acute Pancreatitisin a more than threefold increase in serum amylase or lipase
levels over controls and elevated ALT and bilirubin levels,
which are markers consistent with human biliary AP,5255
and no mortality for 5 days (see Materials and Methods).
Lipase Inhibitors Do Not Interfere with the Initiation
of AP
We ﬁrst studied the effect of GTLO or GTLC on the pa-
rameters of biliary AP (Figure 2). GTL caused a greater than
threefold increase in serum amylase (4273  1017 U/L)
above normal (unoperated on controls, 621  31 U/L)
(Figure 2A). Serum bilirubin and ALT levels were elevated in
the GTL group (Figure 2, B and C). These ﬁndings are
compatible with the deﬁnition of biliary AP.52e55 Animals
from the GTLO and GTLC groups sacriﬁced on the same day
as the ones with GTL-induced pancreatitis (day 1) had similar
serum amylase and bilirubin levels compared with the GTL
group (Figure 2A) or to the rats that only had ligation of the
biliopancreatic duct. The serum ALT level, although signif-
icantly less in the GTLO group (5.3-  0.8-fold control)
compared with the GTL group (33-  15-fold control,
P Z 0.009), remained signiﬁcantly elevated in the GTLO
group compared with controls (52  10 U/L, P Z 0.008).
The extremely high ALT levels in the GTL group may be
related to mortality and an associated shock-liverelike pic-
ture. The bilirubin and ALT levels in the GTLO and GTLC
groups at 5 days were not signiﬁcantly different from the
levels in rats that only underwent ligation of the bil-
iopancreatic duct. These ﬁndings suggest that administration
of lipase inhibitors does not interfere with the induction of
biliary AP and were conﬁrmed in in vitro studies that found
that, although orlistat and cetilistat prevented hydrolysis of
GTL (Supplemental Figure S1A), they do not interfere with
cell death induced by LA (Supplemental Figure S1B).
Lipase Inhibition Reduces the Increase in Serum UFAs
Associated with GTL-Induced Pancreatitis
We then compared the effect of the lipase inhibitors on serum
lipase and serum FAs to study their efﬁcacy in inhibiting
lipases in vivo. GTL administration resulted in a large in-
crease in serum lipase over controls (6443  1619 U/L
versus 16  15 U/L, P < 0.001), and both the GTLO
(244  61 U/L, P Z 0.001 versus GTL) and GTLC groups
(788  397 U/L, P < 0.035 versus GTL) had signiﬁcantly
reduced lipase levels, which, however, were elevated above
controls in these groups at day 1 (Figure 3A). Consistent with
the lipolysis of triglyceride and the release of the free FAs,
there was an increase in serum UFAs both in concentration
(1561  628 mmol/L versus 94  14 mmol/L in controls,
P < 0.001) (Figure 3B) and proportion (60.8%  1.6%
versus 43.9%  3.2% in controls, P < 0.001) (Figure 3C),
with a corresponding decrease in SFA proportions in the GTL
group. The lipase inhibitors orlistat and cetilistat signiﬁcantly
prevented this GTL-induced increase of UFAs in bothThe American Journal of Pathology - ajp.amjpathol.orgconcentration and proportion (Figure 3, B and C). These
ﬁndings, along with the in vitro ﬁndings that orlistat and
cetilistat reduce glycerol generation from GTL incubated with
pancreatic acini (Supplementary Figure S1A), support the
role of orlistat and cetilistat as lipase inhibitors in this model.1777
Figure 4 Inhibition of lipolysis is associated with a reduction
in necrotizingpancreatitis. Gross appearance of the entire pancreas
from eight different animals, including the duodenum in the upper
part of the image and the spleen in the lower part, showing hem-
orrhagic pancreatic necrosis (black arrows) in the GTL group (A),
which are markedly reduced in the GTLO (B) and GTLC (C) groups.
There was only one animal in the GTLC group that had hemorrhagic
necrosis restricted to the head of the pancreas; this was the only
death in this group. The gross images were collected on day 5 in the
GTLO and GTLC groups, and bile staining is visible in some of the
pancreata consistent with persistent obstruction from the ligature.
Representative images of pancreatic histologic sections obtained
on day 1 stained with H&E and photographed with a 2 objective
from a control rat (D) and rats treated with GTL (E), GTLO (F), and
GTLC (G). Note the sheets of necrotic cells with a few surviving
islands (yellow outline) in E, which are reduced in F andG, despite
showing edema, inﬂammatory cells, and a few hemorrhages (yel-
low arrows) consistent with mild AP. Comparisons between the
groups are depicted with box plots quantifying the amount of
pancreatic necrosis as mean (dashed line), median (solid line), the
25th and 75th percentiles (upper and lower parts of the bars), the
10th and 90th percentile (whiskers), and the outliers (dots) and
showing that GTL-induced pancreatic necrosis is prevented by GTLO
and GTLC on day 1 and day 5 (H). *P < 0.05 versus control;
yP< 0.05 versus the GTL group. Original magniﬁcation:4 (DeG).
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Necrosis
GTL injection resulted in gross evidence of severe hemor-
rhagic pancreatitis within the ﬁrst day. Pancreatic hemor-
rhages were seen mostly in the body and tail (Figure 4A), and
the whole pancreas had a necrotic appearance. Histologi-
cally, this was seen as sheets of necrotic parenchyma with a
few surviving islands. Both orlistat (Figure 4B) and cetilistat
(Figure 4C) reduced gross evidence of pancreatic hemor-
rhages and necrosis. Histological appearance in control,
GTL, GTLO and GTLC groups is shown (Figure 4, DeG)
with a few scattered hemorrhages in the latter two groups. A
total of 72.1% þ/ 10.6% of the parenchyma was necrosed
in the GTL group (Figure 4H). On histologic quantiﬁcation of
the necrosis, both orlistat and cetilistat signiﬁcantly reduced
the necrotic area at day 1 (1.1% 0.3% versus 8.3% 6.5%,
both with P< 0.001 versus GTL) and at day 5 (2.4% 0.3%
versus 5.0%  1.6%, both with P < 0.001 versus GTL).
These ﬁndings were no different from rats that only had
ligation of the biliopancreatic duct. These ﬁndings are
consistent with previous studies that report that UFAs cause1778acinar necrosis,29,39 orlistat and cetilistat prevent GTL-
induced cell death in vitro (Supplementary Figure S1, C
and D), and these agents are efﬁcacious in reducing serum
lipase and UFA generation (Figure 3).
Lipase Inhibition Reduces the Increase in Serum
Cytokines Associated with GTL-Induced Pancreatitis
Because we have previously29 found that UFAs up-regulate
proinﬂammatory mediators such as CXCL1/IL-8/keratinocyte
chemoattractant (KC) and tumor necrosis factor-a in vitro and
that serum levels of IL-6, monocyte chemotactic protein-1,
tumor necrosis factor-a, and resistin follow the course of
lipotoxicity in a mechanistically distinct model, we examined
whether UFA reduction with lipase inhibition is also associ-
ated with a reduction in inﬂammatory mediator levels. Serum
levels of IL-1b,56 IL-65760, IL-8,57,60,61 and IL-18,61e63 all
of which have been previously reported to be increased in
human SAP, were measured on both day 1 and day 5. GTL
induced a signiﬁcant increase in cases (Figure 5). Lipase in-
hibition resulted in a signiﬁcant reduction of these at day 1 and
day 5, with the exception of cetilistat not reducing IL-1b onajp.amjpathol.org - The American Journal of Pathology
Figure 5 Lipase inhibition results in a reduc-
tion of serum inﬂammatory cytokine levels. Serum
levels of IL-1b (A), KC/GRO (B), IL-6 (C), and IL-
18 (D) as measured in controls (CON) and ani-
mals with an intraductal infusion of GTL at the
time when they were moribund (GTL) and those
with an infusion of GTLO and GTLC on day 1 and
day 5. Comparisons between the groups are
depicted with box plots showing mean (dashed
line), median (solid line), the 25th and 75th per-
centiles (upper and lower parts of the bars), the
10th and 90th percentile (whiskers), and the
outliers (dots). Note the signiﬁcant reduction in
most of these in lipase inhibitoretreated groups
compared with the GTL group. *P < 0.05 versus
control; yP < 0.05 versus the GTL group.
UFAs Worsen Acute Pancreatitisday 1 and IL-18 on day 5 (Figure 5, A and D). Notably, the
only animal that had died in the cetilistat group had elevated
levels of serum IL-18 (see below). In addition, the IL-1b and
IL-18 levels in these instances were not signiﬁcantly different
from controls (Figure 5, A and D). Thus, lipase inhibition
in vivo is associated with a reduction in the inﬂammatory
response that is associated with the hydrolysis of the unsat-
urated triglyceride GTL.
Lipase Inhibition Prevents Multisystem Organ Failure
and Improves Mortality Associated with GTL-Induced
Pancreatitis
Rats receiving GTL had 100% mortality within a day
(Figure 6A). In rats administered the lipase inhibitors along
with GTL, 0 of 10 died in the GTLO group and 1 of 10 died
in the GTLC group when followed up for 5 days
(Figure 6A). This ﬁnding was associated with GTL-induced
lung injury, as evidenced by an increase in TUNEL-positive
apoptotic cells in the lung (Figure 6B) as occurs in acute
respiratory distress syndrome associated with the infusion of
the UFA oleic acid.64 Compared to controls (Figure 6C),
GTL infusion resulted in large number of apoptotic cells in
the lungs (Figure 6D). There was a signiﬁcant reduction of
apoptotic cells in the GTLO and GTLC groups (Figure 6, E
and F), in both animals electively sacriﬁced on day 1 and
those at the end of the 5-day study. We also measured serum
BUN level and renal injury because these factors were a part
of the spectrum ofmultisystem organ failure. GTL resulted in
a signiﬁcant increase in BUN (88  22 mg/dL versus 16 1
mg/dL in controls, P < 0.001, Figure 7A), which was
signiﬁcantly reduced in the GTLO group at day 1 and day 5
(25 5 mg/dL versus 19 1 mg/dL, P< 0.006 versus GTLThe American Journal of Pathology - ajp.amjpathol.orgfor both) and was reduced in the GTLC group only at day 5
(51  13 mg/dL at day 1, P Z 0.40 versus GTL, and
18 6.mg/dL at day 5, P< 0.001 versus GTL, Figure 7A).
The levels in the GTLO or GTLC groups were no different
from rats that only had ligation of the biliopancreatic duct.
Compared to controls (Figure 7B), GTL resulted in renal
tubular injury seen on TUNEL staining (Figure 7C), as
noted previously in the IL-12/18 model of SAP in obese
mice29 and with the infusion of the UFA oleic acid,65 with
marked improvement in the GTLO and GTLC groups
(Figure 7, D and E). Therefore, inhibition of unsaturated
triglyceride lipolysis using two distinct lipase inhibitors
during SAP is associated with a reduction in UFA genera-
tion and a reduction of lung and renal injury.
Discussion
Using conditions that simulated the most common cause (ie,
biliary AP) and risk factor of SAP (ie, obesity-associated
increase in intrapancreatic fat and high UFA amounts in our
patients) noted in our patients, we found that preventing
acute generation of UFAs, which are formed by the hy-
drolysis of intrapancreatic triglyceride (normally stored
within adipocytes) by using two distinct lipase inhibitors,
results in a reduction of local necrosis, inﬂammatory
mediator levels, prevention of multisystem organ failure,
and improved survival. This, however, occurs without a
reduction in markers of biliary AP (ie, an increase in serum
ALT, bilirubin, or amylase within 24 hours of onset of the
disease), signifying that lipase inhibition does not interfere
with the initiation of biliary AP.
We did not inject bile acids or salts into the pancreatic
ducts to cause biliary AP and instead used a model of1779
Figure 6 Inhibition of lipolysis improves sur-
vival and reduces apoptotic cells in the lungs.
Kaplan-Meyer 5-day survival curve of rats infused
with GTL (red), GTLO (green), and GTLC (blue) (A).
Note that there is 100% mortality in the GTL group
within 24 hours, which is signiﬁcantly reduced in
the GTLO and GTLC groups at 5 days (P < 0.001).
Comparisons between the groups are depicted with
box plots showing mean (dashed line), median
(solid line), the 25th and 75th percentiles (upper
and lower parts of the bars), the 10th and 90th
percentile (whiskers), and the outliers (dots) (B)
and representative images of TUNEL-positive cells
in the lungs in controls (C) and animals treated
with GTL (D), GTLO (E), and GTLC (F). Black arrows
point to the numerous apoptotic cells in the GTL
group. *P < 0.05 versus control; yP < 0.05 versus
the GTL group. Original magniﬁcation: 40 (CeF).
Durgampudi et albiliopancreatic duct ligation alone or with injection of GTL,
GTLO, or GTLC. There are several reasons for this pref-
erence: i) the fact that commonly used concentrations (3% to
5%)66 of agents such as sodium taurocholate to induce se-
vere biliary AP result in local concentrations ranging from
60 to 100 mmol/L, which are 5- to 100-fold above the
critical micellar concentration,67 resulting in a detergent
effect on cell membranes that they contact, and we are not
aware of any human studies to verify the appropriateness of
these concentrations; ii) FA toxicity at concentrations much
below those noted in the PPNC occurs along with the
release of calcium from thapsigargin sensitive intracellular
stores29 unlike detergent-induced damage of cell mem-
branes, resulting in extracellular calcium inﬂux; iii) recent
expert reviews have questioned the relevance of bile injec-
tion to the pathogenesis of biliary AP12 and argue in favor of
the consequences of duct ligation alone; iv) duct ligation
alone resulted in criteria fulﬁlling mild biliary AP5255 (see
Materials and Methods for details); v) the injection of GTL
in amounts equivalent to a 5% to 10% intrapancreatic fat1780area, which is in the range of intrapancreatic fat
(23.4%  4.3%) and fat necrosis (12.6%  3.4%) noted in
obese humans with SAP29, resulted in SAP in our model;
and vi) the intraductal route allows for hydrolysis of the
triglyceride by pancreatic lipases as occurs in fat necrosis in
human AP29,39,45,46 (Figure 1, C and D) and from the
basolateral leakage45,46,48,49,68 of lipases during AP causing
hydrolysis of adipocyte triglyceride. Therefore, this model is
highly relevant to human disease because it fulﬁlls criteria
of human biliary AP and the pathophysiologic features
resulting from basolateral leakage, mimics increased intra-
pancreatic fat that occurs in obesity,29,39,69 and is associated
with worse outcomes in patients with AP.68,29,70
Both cetilistat71 and orlistat are highly lipophilic, which
facilitated their dissolution in the GTL without the need of a
vehicle. Although cetilistat is a benzoxazinone71 lipase in-
hibitor, orlistat reacts with the nucleophilic serine of lipases
via its b-lactone moiety, resulting in a covalent com-
plex.72,73 Both agents improved outcomes in the SAP model
studied, along with inhibiting lipase activity and preventingajp.amjpathol.org - The American Journal of Pathology
Figure 7 Inhibition of lipolysis prevents sustained renal failure and
renal tubular injury induced by biliary SAP. Box plots of serum BUN levels in
the various groups showing mean (dashed line), median (solid line), the
25th and 75th percentiles (upper and lower parts of the bars), the 10th and
90th percentile (whiskers), and the outliers (dots) (A). Note that the BUN
level is signiﬁcantly increased in the GTL group at the time of mortality.
Although the animals in the GTLC group developed transient renal failure at
day 1, this normalized by day 5. TUNEL staining of controls (B) and rats
treated with GTL (C), GTLO (D), and GTLC (E) produces strong evidence of
tubular damage (black outline) in the GTL group, which is prevented in the
GTLO and GTLC groups. *P < 0.05 versus control; yP < 0.05 versus the GTL
group. Original magniﬁcation: 40 (BeE).
UFAs Worsen Acute Pancreatitisthe increase in serum UFAs, supporting the role of lipolytic
generation of UFAs in the adverse outcomes of SAP. The
advantage of pharmacologic inhibition over currently
available genetic knockouts of lipases is the ability of the
inhibitors to reduce the activity of all lipases expressed in
the pancreas74 (Singh Lab, unpublished data). This is
beneﬁcial because lipases seem to have redundant roles as
evidenced by mice with a deletion of a single pancreatic
lipase gene achieving normal adult weight,75 whereas dual
lipase knockouts76 experience embryonic and neonatal
mortality, which would also prevent studies in adult mice.
We have previously found UFAs to induce cell death and
to up-regulate inﬂammatory mediators, including CXCL1,
CXCL2, and tumor necrosis factor-a.29 This dual role has
relevance to the end points noted in this study based on the
fact that both lipase inhibitors prevent large areas of
pancreatic necrosis and massive increase of cytokinesThe American Journal of Pathology - ajp.amjpathol.orginduced by GTL. In addition, GTL-induced lung injury and
renal failure are also prevented by lipase inhibition. Although
the increase in necrosis is likely due to these formed UFAs
inhibiting mitochondrial complexes I and V and conse-
quently reducing ATP levels,29 it remains unclear whether it
is the UFAs themselves or the inﬂammatory cytokines
generated that result in worse systemic outcomes and mor-
tality. Interestingly, the published literature supports the
ﬁnding that lipotoxicity results in these conditions, as is noted
in oleic acideinduced acute lung64 and renal injury, during
which the levels of IL-1b, IL-6,77 and tumor necrosis factor-a
are also increased. The role these cytokines may play remains
to be explored, with recent studies reporting them to play a
protective role as evidenced by IL-678 improving lung
inﬂammation and IL-8 improving survival in hemorrhagic
shock.79 In addition, studies looking at patients with a high
BMI having SAP have found this to be independent of the
levels of cytokines, such as IL-1b and IL-6.1
In contrast to this study, where we found the beneﬁts of
targeting a modiﬁer of AP outcomes (ie, the lipolysis of
intrapancreatic fat), the relevance of a target to improving
outcomes in AP has classically been based on revealing that
the target plays a role in multiple models initiated by different
insults. Examples include trials studying the efﬁcacy of serine
protease and trypsin inhibitors, such as gabexatemesylate,22,80
aprotinin,26,80 and nafamostat,24,81 in improving AP outcome,
based on that rationale that intrapancreatic active trypsin is
noted during mechanistically dissimilar AP models, such as
caerulein, choline deﬁcient ethionine supplemented, and
taurocholate-induced AP.11,16,17 However, there is no clear
evidence that trypsin inhibition improved AP outcomes in
clinical trials.19,21 Further proof that targeting an initiator of
AP, such as trypsin, may not affect outcomes, such as necrosis
or mortality, comes from the observation that patients with
hereditary pancreatitis due to trypsinogen gene mutations,
such as PRSS1 (resulting in increased intracellular amounts of
the active enzyme), do not experience SAP.82 Last but not
least, the severity of an AP attack is typically unrelated to its
cause, but obesity has been repeatedly reported to be associ-
ated with adverse outcomes.6e8,29,70
The clinical part of this study may be limited by its small
size, the fact that the predominant cause was biliary AP, the
lack of data on the reason for intervention on the PPNCs, the
identity of which collections were infected, and the changes
that may have taken place during the period that the
collection formed (because the earliest time to collection of
the samples from onset of AP was 4 weeks). Although the
small size could result in a type 2 error and us falsely
estimating the absolute amount of UFAs to be higher than
the amount of SFAs (2.7  1.0 mmol/L versus 1.0  0.3
mmol/L, P Z 0.033, Figure 1A), the facts that UFAs
formed a signiﬁcantly higher percentage (68.5%  3.0%
versus 31.7%  2.9% for SFAs, P < 0.001) of the overall
FA content (3.8  1.3 mmol/L) in the PPNCs and that the
UFAs necrose acinar cells at 300 mmol/L in contrast to the
SFAs (which do not even at 1.2 mmol/L)29 minimize the1781
Durgampudi et alsigniﬁcance of this error. We cannot explain our patient
population being enriched in biliary AP or justify the lack of
data regarding which of the collections were infected.
However, infections would not change our conclusions
because we do not dispute the clinical tenet that infected
collections must be treated. Moreover, UFA formation
would occur primarily from the hydrolysis of visceral
adipocyte triglyceride by lipases, which are produced by the
exocrine pancreas and not infections. Although potential
mediators and their concentrations may have changed over
the time the collections accumulated, a period of >4 weeks
from the onset of AP to the time of intervention is consistent
with the current guidelines for such interventions.10,34,83
In summary, using a model of biliary AP relevant to our
patients, we found that pharmacologic inhibition of lipolysis
using two distinct lipase inhibitors reduces the generation of
UFAs, which are normally enriched in pancreatic necrosis.
This inhibition results in ameliorating pancreatic necrosis,
the increase in serum cytokines, and lung and renal injury
without interfering with the increase in markers of biliary
AP. Therefore, targeting acute lipotoxicity improves out-
comes in severe biliary acute pancreatitis without affecting
its initiation.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.02.015.
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